meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced UC (mUC) - 2nd Line (L2)
mUC - L2 - all population
2
mUC - L2 - PDL1 positive
3
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
pembrolizumab based treatment
pembrolizumab alone
versus all
vs chemotherapy
vs Standard of Care (SoC)
All patients
PD-L1 < 1%
PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
deaths (OS)
mUC - L2 - all population
metastatic/advanced UC (mUC) - 2nd Line (L2)
mUC - L2 - all population
mUC - L2 - PDL1 positive
metastatic/advanced UC (mUC) - 2nd Line (L2)
mUC - L2 - PDL1 positive
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open